A new trial update dated August 28, 2026 reports that a study of oral ecnoglutide tablets is now recruiting participants. The study, registered as NCT07243171, is titled "A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity." The trial is listed as Phase Ib/IIa and is designed to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral formulation. Participants are Chinese adults with overweight or obesity, according to the study title. The current status of the trial is recruiting, meaning enrollment is actively underway as of the listed date.
No results, efficacy data, or safety findings have been posted for this study at this stage. The event data confirms only the trial's design elements, phase, and recruitment status as recorded on ClinicalTrials.gov. Ecnoglutide remains classified as an unapproved compound under research investigation, and this study represents an early-stage clinical evaluation. Further updates would be expected as the trial progresses through its recruitment and evaluation phases. Readers interested in background on this compound can consult the ecnoglutide overview for additional context.